Marksans Pharma: Unaudited financial results for the quarter and half year ended September 30, 2026
Marksans Pharma (MARKSANS) filed a disclosure titled "Unaudited financial results for the quarter and half year ended September 30, 2026". The company is valued at about ₹14,209 crore.
What happened
Marksans Pharma (MARKSANS) filed a disclosure with the exchanges on 4 November 2026 at 01:34 PM titled "Unaudited financial results for the quarter and half year ended September 30, 2026".
From the filing: "Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026."
Company snapshot
Marksans Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹14,209 crore.
The stock last traded at ₹313.6, against a 52-week range of ₹155–₹351 (10.7% below the high).
Before this filing the shares had moved −3.2% over the month and +17.2% over three months. Average daily turnover over the last 20 sessions was about ₹39.54 crore.
Promoters held 43.87% at the end of Q1 FY27. Foreign institutions owned 17.47% and domestic institutions 6.19%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 620 | 58.3 | 1.29 |
| Q2 FY26 | 720 | 98.3 | 2.17 |
| Q3 FY26 | 754 | 113.2 | 2.5 |
| Q4 FY26 | 856 | 148.1 | 3.27 |
| Q1 FY27 | 841 | 157.2 | 3.47 |
What history shows
This is not the company's first results disclosure: BCEIE has 4 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 10.2% on average the next trading day and was up 14.7% on average after five days (3 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,609 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 12 Aug 2026 | Result For The Quarter Ended June 30, 2026 | +8.8% | +17.2% |
| 12 Aug 2026 | Board Meeting Outcome for Outcome Of Board Meeting Held On 12 August… | +8.8% | +17.2% |
| 26 May 2026 | Audited Financial Results For The Quarter And Year Ended 31 March,… | +13.2% | +9.5% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 4 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Marksans Pharma achieves record revenue of ₹940 crore in Q2FY27
- Marksans Pharma hits record ₹940 crore quarterly revenue
- Marksans Pharma Q2 results: Net profit jumps 43.4% YoY to Rs 141 crore, revenue rises 30.6%
- Marksans Pharma reports ₹855.42 crore profit for Q2 FY27
- Marksans Pharma reports Q2 FY27 standalone and consolidated results
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.